Artificial intelligent diagnostic system for early Echinococcosis based on novel biomarkers

Early Echinococcosis diagnosis system based on novel biomarkers

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200060516

Enrollment

Unknown

Registered

2022-06-04

Start date

2020-07-01

Completion date

Unknown

Last updated

2024-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Echinococcosis

Interventions

Gold Standard:Anti-hydatid IgG was positive and imaging examination supported the diagnosis of hydatid disease

Index test:Screening effective biomarkers (cfDNA) from body fluids of patients with Echinococcosis as potential diagnostic indicators for early screening of Echinococcosis. Based on the selected bioma

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Anti-hydatid antibody IgG(+) and two clinical experts supported the diagnosis of hydatid disease based on two or more imaging tests; 2. No surgical treatment for hydatidosis or recurrence of hydatidosis after surgical treatment.

Exclusion criteria

Exclusion criteria: 1. Patients with primary liver cancer and other space-occupying liver diseases; 2. Complicated with other malignant tumors; 3. Those with connective tissue disease or autoimmune disease; 4. Patients with a history of acute or chronic hepatitis and other liver function impairment; 5. Other infectious diseases: such as pulmonary and hepatobiliary bacterial infection, tuberculosis, etc.; 6. Women who are pregnant or breastfeeding.

Design outcomes

Primary

Measure	Time frame
cell free DNA;	—

Countries

China

Contacts

Public ContactLi Chunyang

West China Hospital, Sichuan University

lichunyang@wchscu.cn+86 18581866992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026